Kassel
Kassel
Kassel, Germany76 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07214779 | |
| An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Recruiting | Phase 2 | 2026-10-09 | NCT07197866 | |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT07100080 | |
| A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Active, not recruiting | Phase 2 | 2026-10-09 | NCT06568237 | |
| Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-09 | NCT05687266 | |
| Registry for Duchenne and Becker Muscular Dystrophy | Becker muscular dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Not stated | 2026-10-08 | NCT07402122 | |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-07 | NCT05512364 | |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 3 | 2026-10-06 | NCT07174310 | |
| A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | Moderate to Severe Glabellar Lines | Active, not recruiting | Phase 3 | 2026-10-01 | NCT07435428 | |
| A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease | Parkinson disease, autosomal recessive early-onset Parkinson disease 6, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Active, not recruiting | Phase 2 | 2026-10-01 | NCT06015841 | |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07064473 | |
| Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 4 | 2026-09-30 | NCT06571149 | |
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Not stated | 2026-09-30 | NCT04579367 | |
| WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment) | Stroke, Acute, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-09-29 | NCT04701684 | |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 2 | 2026-09-28 | NCT05242471 | |
| A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | Chronic Migraine | Recruiting | Phase 3 | 2026-09-25 | NCT07018713 | |
| A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | Episodic Migraine | Recruiting | Phase 3 | 2026-09-25 | NCT07018700 | |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-09-25 | NCT06120140 | |
| A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05757869 | |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | Non-squamous Non-small Cell Lung Cancer | Recruiting | Phase 3 | 2026-09-23 | NCT06627647 | |
| Pan Tumor Rollover Study | cancer, neoplasm | Recruiting | Phase 2 | 2026-09-23 | NCT03899155 | |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-18 | NCT06692738 | |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-09-17 | NCT06858839 | |
| A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-09-17 | NCT06340568 |